PT666. Check an effeciency About the Suvorexant with Combining Other Sleep Promoting Medicines

نویسندگان

  • Toshiaka Tsuneoka Akira Iwanami
  • Sayaka Matsuzaki
  • Haruhisa Ohta
  • Nobuyuki Saga
  • Hiroki Sasamori
  • Hiroki Yamada
  • Sachiko Yokoyama
چکیده

s | 43 nights of wrist actigraphy. The mean age was 54.3 years (range 34 to 83). To reveal factors associated with insulin resistance and age, statistically significant variables in univariate regression analyses were entered into multivariate regression analyses. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). In women, higher sleep onset latency (SOL) was associated with higher insulin resistance after adjustment for possible confounding factors including age, smoking, obesity, diabetes, depression, and inflammatory cytokines. Also, higher SOL was associated with higher interleukin (IL)-6 and C-reactive protein (CRP) levels. After adjusting for covariates, no sleep measures were associated with insulin resistance, IL-6, or CRP in men. The mediation analysis showed that higher SOL is associated with insulin resistance both directly and indirectly. Difficulty initiating sleep contributes to insulin resistance development, especially in middle-aged women. A combination of inflammatory pathway activation and physiological hyperarousal may be one of the key underlying mechanisms. PT665 Prevalence of Sleep Problems and Its Impact on Anxiety, Depression and Quality of Life in Korean Fire Fighters Young-Suck Paik, M.D., Ph.D.1, Kuy-Hang Lee, M.D., Ph.D.1, Hye-Jin Lee, Ph.D.,2, Sang Yeol Lee, M.D.,Ph.D. 1 1Department of Psychiatry, Wonkwang University School of Medicine, Iksan, Korea Wonkwang Brain, Behavior and Mental Health Institute 2Department of Public Health, Wonkwang University Graduate School,

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant

Insomnia, a highly prevalent disorder, can be detrimental to patients' overall health and worsen existing comorbidities. Patients may have acute episodes of insomnia related to a traumatic event, but more commonly insomnia occurs chronically. While proper sleep hygiene and behavioral therapy play important roles in the nonpharmacologic management of short-term and chronic insomnia, medications ...

متن کامل

Suvorexant: something new for sleep?

Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsine...

متن کامل

The Effects of Benzodiazepine and Nonbenzodiazepine Agents, Ramelteon, Low-dose Doxepin, Suvorexant, and Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists on Sleep and Wakefulness

Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the benzodiazepine (BZD) and non-BZD receptor allosteric modulators, the melatonin receptor agonist ramelteon, low-dose doxepin, and suvorexant. One of the drawbacks of the BZDs is their known reduction in both N3 sleep [also known as slow wave sleep or delta sleep and charac...

متن کامل

Is suvorexant a better choice than alternative hypnotics?

Suvorexant is a novel dual orexin receptor antagonist (DORA) newly introduced in the U.S. as a hypnotic, but no claim of superiority over other hypnotics has been offered.  The manufacturer argued that the 5 and 10 mg starting doses recommended by the FDA might be ineffective.  The manufacturer's main Phase III trials had not even included the 10 mg dosage, and the 5 mg dosage had not been test...

متن کامل

PT653. Experience using suvorexant to treat delirium

s | 39 PT652 Neuropeptide receptor genes polymorphism and sleep disorders V.V. Gafarov1, E.A. Gromova1, M. I. Voevoda1, I.V. Gagulin1, V.N. Maximov1, A.V.Gafarova1, D.O. Panov1 1. FSBI Institute of Internal and Preventive Medicine Abstract Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45–64 years of Novosibirsk. Methods: ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 19  شماره 

صفحات  -

تاریخ انتشار 2016